Gilead Sciences Donates Remdesivir to Uganda

On June 12, 2026, Gilead Sciences (NASDAQ:GILD) announced a donation of over 2,000 vials of remdesivir to Uganda for the treatment of Ebola Bundibugyo virus disease. The company emphasized its commitment to global health emergencies and collaboration with partners.

By Jeff Lewis Wed, June 17, 2026 at 8:34 PM GMT+3 2 min read · Yahoo Finance · June 17, 2026, 17:34 UTC

Gilead Sciences Donates Remdesivir to Uganda

Tickers: $GILD $MRK

Topics: Ebola Outbreak Global Health Pharmaceuticals

Read the full article at Yahoo Finance

More World news

BlueMatrix Completes Acquisition of AI-Enabled Research Platform Aiera PR Newswire · November 12, 2026, 15:15 UTC
U.S. Lawmakers Respond to Jensen Huang's Resignation as Nvidia CEO Seeking Alpha · November 12, 2026, 15:12 UTC
OpenAI Secures $15 Billion in New Funding at $1.25 Trillion Valuation Seeking Alpha · November 12, 2026, 15:13 UTC
Digi International Shares Fall 18% Following Fiscal Q4 Earnings Release Seeking Alpha · November 12, 2026, 15:13 UTC
Pomerantz Law Firm Investigates Artiva Biotherapeutics Following Program Discontinuation and Fatal Safety Events PR Newswire · November 12, 2026, 15:15 UTC
Major Corporate Earnings Scheduled for Release After Thursday Market Close Seeking Alpha · November 12, 2026, 15:00 UTC
U.S. Existing Home Sales Decline More Than Expected in October Seeking Alpha · November 12, 2026, 15:03 UTC
Ascendis Pharma Reports Strong Q3 2026 Results Driven by Yorvipath Growth Motley Fool · November 12, 2026, 15:09 UTC
Pomerantz Law Firm Investigates Omeros Corporation Following Regulatory Setbacks PR Newswire · November 12, 2026, 15:10 UTC
Pomerantz Law Firm Investigates Innodata Inc. Following Mass Layoffs and Stock Price Drop PR Newswire · November 12, 2026, 15:10 UTC